KOREA WHO
-
-
-
CEO of Samsung Bioepis
Christopher Hansung Ko
Global-Minded Biotech Expert, Laying Foundation for Samsung Group's Bio-Business
-
Last Updated on Sep 3, 2024
-
CEO of Samsung Bioepis
Life Summary
Christopher Hansung Ko is the President and CEO of Samsung Bioepis.
As the founding CEO of Samsung Bioepis, he oversees the research and development of biosimilars (biopharmaceutical generics).
With Samsung BioLogics acquiring full ownership of Samsung Bioepis, he is exploring new ventures, including new drug development.
Born on April 20, 1963, in Busan, according to the lunar calendar, he immigrated to the United States during his middle school years. He holds American citizenship and is known by the name 'Christopher Ko' in the United States.
He graduated from Prospect High School in California and majored in Biochemistry at the University of California, Berkeley.
He earned his Master’s and Doctorate degrees in Genetic Engineering from Northwestern University.
He began his career at the biotech venture company Dyax.
He has held positions as the Head of BioHealth Lab at Samsung Advanced Institute of Technology and as Executive Vice President in the New Business Development Team at Samsung Electronics.
He was appointed as CEO when Samsung Bioepis was established.
He has been developing biosimilars to target the global markets, including Europe and the United States.
Alongside John Rim, President and CEO of Samsung BioLogics, he is a key figure responsible for Samsung Group’s bio-business.
#SamsungBioepis #biosimilars #ChristopherKo #biotech #SamsungBioLogics #geneticengineering #biopharma #globalmarkets #drugdevelopment #biohealth
As the founding CEO of Samsung Bioepis, he oversees the research and development of biosimilars (biopharmaceutical generics).
With Samsung BioLogics acquiring full ownership of Samsung Bioepis, he is exploring new ventures, including new drug development.
Born on April 20, 1963, in Busan, according to the lunar calendar, he immigrated to the United States during his middle school years. He holds American citizenship and is known by the name 'Christopher Ko' in the United States.
He graduated from Prospect High School in California and majored in Biochemistry at the University of California, Berkeley.
He earned his Master’s and Doctorate degrees in Genetic Engineering from Northwestern University.
He began his career at the biotech venture company Dyax.
He has held positions as the Head of BioHealth Lab at Samsung Advanced Institute of Technology and as Executive Vice President in the New Business Development Team at Samsung Electronics.
He was appointed as CEO when Samsung Bioepis was established.
He has been developing biosimilars to target the global markets, including Europe and the United States.
Alongside John Rim, President and CEO of Samsung BioLogics, he is a key figure responsible for Samsung Group’s bio-business.
#SamsungBioepis #biosimilars #ChristopherKo #biotech #SamsungBioLogics #geneticengineering #biopharma #globalmarkets #drugdevelopment #biohealth